Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Neoadjuvant Complete Hormonal Blockade Followed by Neoadjuvant Chemotherapy for Resectable Hormone Receptor Positive, HER-2/Neu Negative Breast Cancer, A Phase II Study

NCT00194792 is registered in ClinicalTrials.gov with University of Washington as lead sponsor.

NCT NCT00194792
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00194792 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Neoadjuvant Complete Hormonal Blockade Followed by Neoadjuvant Chemotherapy for Resectable Hormone Receptor Positive, HER-2/Neu Negative Breast Cancer, A Phase II Study
Lead sponsor
University of Washington
Phase
Phase 2
Overall status
Terminated
Start date
August 31, 2005
Completion date
July 31, 2011
Enrollment
28 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

estrogen receptor-positive breast cancer, her2-negative breast cancer, progesterone receptor-positive breast cancer, stage i breast cancer, stage ii breast cancer, stage iiia breast cancer